Haiming Yu1, Junlan Yang1, Shunchang Jiao1, Ying Li1, Wei Zhang2, Jiandong Wang3. 1. Department of Medical Oncology, General Hospital of PLA Beijing, China. 2. Department of Pathology, 401 Hospital of PLA Qingdao, China. 3. Department of General Surgery, General Hospital of PLA Beijing, China.
Abstract
PURPOSE: T-box transcription factor 21 (T-bet) is a key lineage-defining transcription factor. The purpose of this study was to verify the relationship between expression in primary tumors and prognosis of breast cancer. METHODS: T-protein expression was immunohistochemically detected on surgically-obtained tumor samples of 130 (stage I-III) invasive breast carcinomas from Chinese subjects, who were followed up for a mean time of 112 months. RESULTS: T-bet was expressed in the nuclei and cytoplasm of both tumor cells and tumor-infiltrating lymphocytes. In LOG-RANK analysis, higher density of interstitial T-bet+ interstitial lymphocytes was related with longer distant disease-free survival (DDFS) (P = 0.047); higher tumor nuclei T-bet expression was related with shorter DFS (P = 0.021) and DDFS (P = 0.026). Cox multivariate analysis showed that density of interstitial T-bet+ interstitial lymphocytes was an independent positive prognostic factor for DFS (HR = 0.474, P = 0.051) and DDFS (HR = 0.414, P = 0.030); tumor nuclei CTLA-4 expression was an independent adverse prognostic factor for DFS (HR = 3.007, P = 0.003), DDFS (HR = 2.931, P = 0.005) and OS (HR = 2.352, P = 0.029). CONCLUSIONS: This study found that, high tumor nuclei T-bet expression in primary tumors of breast cancer was correlated with poor prognosis and high density of T-bet+ interstitial lymphocytes in primary tumors of breast cancer were correlated with favorable prognosis.
PURPOSE: T-box transcription factor 21 (T-bet) is a key lineage-defining transcription factor. The purpose of this study was to verify the relationship between expression in primary tumors and prognosis of breast cancer. METHODS: T-protein expression was immunohistochemically detected on surgically-obtained tumor samples of 130 (stage I-III) invasive breast carcinomas from Chinese subjects, who were followed up for a mean time of 112 months. RESULTS:T-bet was expressed in the nuclei and cytoplasm of both tumor cells and tumor-infiltrating lymphocytes. In LOG-RANK analysis, higher density of interstitial T-bet+ interstitial lymphocytes was related with longer distant disease-free survival (DDFS) (P = 0.047); higher tumor nuclei T-bet expression was related with shorter DFS (P = 0.021) and DDFS (P = 0.026). Cox multivariate analysis showed that density of interstitial T-bet+ interstitial lymphocytes was an independent positive prognostic factor for DFS (HR = 0.474, P = 0.051) and DDFS (HR = 0.414, P = 0.030); tumor nuclei CTLA-4 expression was an independent adverse prognostic factor for DFS (HR = 3.007, P = 0.003), DDFS (HR = 2.931, P = 0.005) and OS (HR = 2.352, P = 0.029). CONCLUSIONS: This study found that, high tumor nuclei T-bet expression in primary tumors of breast cancer was correlated with poor prognosis and high density of T-bet+ interstitial lymphocytes in primary tumors of breast cancer were correlated with favorable prognosis.
Authors: Kristin M Beima; Michael M Miazgowicz; Megan D Lewis; Pearlly S Yan; Tim H-M Huang; Amy S Weinmann Journal: J Biol Chem Date: 2006-02-10 Impact factor: 5.157
Authors: Nikhil S Joshi; Weiguo Cui; Anmol Chandele; Heung Kyu Lee; David R Urso; James Hagman; Laurent Gapin; Susan M Kaech Journal: Immunity Date: 2007-08 Impact factor: 31.745
Authors: Scott M Gordon; Julie Chaix; Levi J Rupp; Junmin Wu; Sharline Madera; Joseph C Sun; Tullia Lindsten; Steven L Reiner Journal: Immunity Date: 2012-01-18 Impact factor: 31.745
Authors: David G DeNardo; Jairo B Barreto; Pauline Andreu; Lesley Vasquez; David Tawfik; Nikita Kolhatkar; Lisa M Coussens Journal: Cancer Cell Date: 2009-08-04 Impact factor: 31.743
Authors: Andrew E Teschendorff; Sergio Gomez; Alex Arenas; Dorraya El-Ashry; Marcus Schmidt; Mathias Gehrmann; Carlos Caldas Journal: BMC Cancer Date: 2010-11-04 Impact factor: 4.430
Authors: S Ladoire; L Arnould; G Mignot; L Apetoh; C Rébé; F Martin; P Fumoleau; B Coudert; F Ghiringhelli Journal: Br J Cancer Date: 2011-07-12 Impact factor: 7.640
Authors: Juan Fang; Xiaoxu Li; Da Ma; Xiangqi Liu; Yichen Chen; Yun Wang; Vivian Wai Yan Lui; Juan Xia; Bin Cheng; Zhi Wang Journal: BMC Cancer Date: 2017-05-26 Impact factor: 4.430
Authors: Sathana Dushyanthen; Paul A Beavis; Peter Savas; Zhi Ling Teo; Chenhao Zhou; Mariam Mansour; Phillip K Darcy; Sherene Loi Journal: BMC Med Date: 2015-08-24 Impact factor: 8.775